• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Supplemental Material: Cost of Home vs Clinic Administration of Paclitaxel in Metastatic Breast Cancer

Publication
Peer-Reviewed
Evidence-Based OncologyFebruary 2021
Volume 27
Issue 2

Home administration of oral paclitaxel and encequidar is associated with potential cost savings for payers compared with clinic administration of intravenous chemotherapy in metastatic breast cancer patients.

Related Videos
Nini Wu, MD, Navista
Jorge García, PharmD, MS, MBA, MHA, FACHE, FACCC
Screenshot of Adam Colborn, JD during an interview
Screenshot of an interview with Stuart Staggs
Stuart Staggs
Lalan Wilfong, MD, during a video interview
dr katherine baker
Dr Julie Patterson, National Pharmaceutical Council
Ben Jones, McKesson/Us Oncology
Kathy Oubre, MS, Pontchartrain Cancer Center
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.